Sharjeel Chaudhry* and Zarmina Ehtesham
Loco-regional control rates and tumour response have increased as a result of advancements in Head and Neck Cancer (HNC) therapy. Moreover, mortality is still high despite advancements in treatment and diagnostic methods. Altered fractionation Radiotherapy (RT) or Chemoradiotherapy (CRT) treatment escalation leads to significant late and early pharyngeal and mucosal toxicities but is related to better outcomes. A sign of HNC that is underdiagnosed in patients is oropharyngeal dysphagia. Dysphagia frequently results from structural, iatrogenic, neuromuscular, and neurological dysfunction. Dysphagia must not be disregarded because it can significantly lower the Quality of Life (QoL).
